France : OSE Immunotherapeutics Receives 9.2 million Grant from Bpifrance "Invest in the Future Program" for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM).
OSE Immunotherapeutics will lead the consortium collaborating on this project named EFFI-CLIN aiming at developing a new generation of checkpoint inhibitor in cancer immunotherapy. The consortium also includes the European Center for Trans plantation and Immunotherapy (CESTI), a public organization based in Nantes (France) and HISTALIM, a SME based in Montpellier (France).
EFFI-CLIN will evaluate the safety and the clinical efficacy of new cancer immunotherapy OSE-172 as a monotherapy and in combination in various indications where myeloid cells represent a poorprognosis factor. The project will include in particular the product manufacturing compliant with pharmaceutical standards, translational studies conducted from tumour tissues to measure the presence of immunological targets including SIRP-alpha, and a clinical program planned until the phase 2.
"We are very happy to support OSE Immunotherapeutics and its partners in this innovative R&D program to serve the future ofunmet medical needs,"said Catherine Borg-Capra, Director of Industrial Innovation sectoral Bpifrance.
Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics, said: "We thankthe Investin the Future Program for supporting us with thisgrantthat wit allow to accelerate the development of our monoclonal antibody platform based in Nantes, in a high-level scientific environment, and to conduct our product OSE-172 to the clinical phase, a step planned for the end of 2018."
Bernard Vanhove, Chief Operating Officer and Head of R&D and International scientific collaborations at OSE Immunotherapeutics, adds: "We are very pleased to collaborate with the highly-skilled teams of CESTI and HISTALIM to conduct this ambitious project and to provide innovative scientific, diagnostic and therapeutic outcomes in immuno-oncology"
Tumours have the particularity of secreting molecules that allow the recruitment and/or generation of suppressor cells that prevent the immune system from eliminating tumour cells. Among the major players in immune dysfunctions promoting tumour growth, pro-tumour and suppressor myeloid cells have been identified (MDSC or Myeloid-Derived Suppressor Cells /TAM orTumour-Associated Macrophages).
OSE Immunotherapeutics was the first to identify the SIRP-alpha target (Signal Regulatory Protein alpha) as a major checkpoint for myeloid cells. The company has developed a selective SIRP-alpha antagonist antibody that transforms the tumour microenvironment by blocking suppressor cells and activating anti-tumour effector cells.
The exploration of SIRP-alpha in key indications will be carried out jointly with CESTI and its various technological platforms. The European Centerfor Transplantation and Immunotherapy Sciences (CESTI)is a University Hospital Institute (IHU B Nantes, headed by Professor Gilles Blancho) focused on the control of the immune response. CESTI benefits from a recognized expertise in immunotherapy and relevant experimental and translational platforms ahead of clinical trials and development of therapeutic innovations. The proximity of these research laboratories with clinicians and patients is an asset forconducting preclinical and translational studies from tissues derived from patients.
The company HISTALIM will develop a tool called HISTOPROFILE, for a help in the decision-making in a perspective of personalized medicine. This tool will use multiplex immunohistochemistry techniques (several targets measured at the same time on the same tissue) coupled with image analyses. The objective is to characterize the immune profile and the biomarkers found in a patient. This will make it possible to define the most appropriate treatment using algorithms integrating the multiple information obtained from a clinical biopsy.
OSE-172 addresses unmet medical needs in immuno-oncology
Current therapeutic strategies in immuno-oncology are largely based on T-lymphocyte checkpoint inhibitors (CKI). The CKIs that target T-lymphocytes have revolutionized oncologic practice, with several products in this class leading to sustained tumour reductions. However, a significant medical need remains because a high percentage of patients do not respond or relapse after an initial response to treatments of this type. The search for new targets is focused on T-lymphocytes, with a significant number of product candidates currently being evaluated. However, research into drugs that target myeloid cells, which are present in large numbers in the tumour microenvironment, is still in the preliminary stages.
Bpifrance is the managing operator for research and development projects structuring competitiveness underthe Investments forthe Future' Program led by the General Investment Commission. The goal of these projects is to frame and organize industry sectors or to generate new ones. They aim to strengthen the positions of French businesses in key markets by providing funding for ambitious programs. More broadly they aim to enhance the economic standing of a network of enterprises, by building or consolidating sustainable collaborative relationships between manufacturing, service industries and research organizations.
[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 22, 2017|
|Previous Article:||United States : Senator Collins Announces $20 Million Grant for Maine Med Research Institute, Tours Cutting-Edge Facility.|
|Next Article:||United States : Capito, Bipartisan Group Introduce Comprehensive G.i. Bill Reforms.|